India's pharmaceutical market (IPM) grew 10.1 per cent year-on-year in March 2026, propelled by robust volume recovery, steady price increases, and a favorable therapy mix, according to a report by India Ratings and Research (Ind-Ra). This acceleration in IPM growth was particularly fueled by the anti-diabetic segment, where GLP-1 generics are rapidly reshaping market dynamics. New product launches, including generic semaglutide, have intensified competition while expanding access to these game-changing therapies for diabetes management.
Understanding IPM Growth Drivers in India's Pharma Landscape
The IPM's double-digit expansion in March 2026 extends a recovery trend observed since December 2025. Volumes have rebounded, complemented by modest pricing and the introduction of innovative products. Ind-Ra attributes this to a shift toward chronic therapies, which now dominate due to India's rising prevalence of lifestyle diseases like type 2 diabetes and obesity.
GLP-1 receptor agonists, such as semaglutide, mimic the glucagon-like peptide-1 hormone to regulate blood sugar, slow gastric emptying, and promote weight loss. In India, where diabetes affects over 100 million people, these agents address both glycemic control and cardiometabolic risks, making their market entry pivotal for IPM growth.
Chronic Therapy Momentum and Volume Recovery
Ind-Ra expects this momentum to persist into FY27, projecting 9-10 per cent year-on-year sales growth. Key drivers include expanding chronic portfolios, sustained volume upticks, and speciality launches. However, pricing controls and escalating competition—especially in high-growth areas like GLP-1—pose challenges.
"Growth drivers across value, volume, and new products have strengthened over the past two quarters. We expect this momentum to sustain in FY27, led by chronic-centric portfolios," said Nishith Sanghvi, Director - Corporates, Ind-Ra.
Chronic therapies outperformed the IPM in the moving annual total (MAT) for March 2026, bolstered by improved diagnosis rates, higher patient adherence, and increasing disease awareness. Positive volume trends across segments signal long-term sustainability beyond mere price hikes.
Anti-Diabetic Therapies Surge Ahead: GLP-1 Generics Take Center Stage
The anti-diabetic therapy category outpaced the broader IPM, achieving 15.5 per cent year-on-year growth in March 2026. This was aided by the late-month launch of generic semaglutide, which sparked immediate demand.
The Indian GLP-1 agonist market expanded to Rs 15.8 billion in MAT March 2026, nearly three times higher than a year earlier. Normalised AIOCD data revealed a two-to-three-fold rise in semaglutide unit volumes, despite generics being available only for the last 10 days of March. Injectable formats drove the surge, with an almost six-fold increase over February 2026.
While volumes soared, value growth trailed, reflecting aggressive pricing and heightened competition post-generic entry. Semaglutide, originally branded as Ozempic or Rybelsus, works by enhancing insulin secretion, suppressing glucagon, and reducing appetite—critical for India's diabetes epidemic.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
"GLP-1 is emerging as a structural growth driver for the anti-diabetic segment. However, rapid generalisation is likely to keep pricing under pressure in the near term," Sanghvi added.
Implications for Patients: Accessing GLP-1 Therapies
For patients with type 2 diabetes, GLP-1 agonists like semaglutide offer superior outcomes in A1C reduction and weight management compared to older therapies like metformin or sulfonylureas. Generic availability could lower costs from Rs 3,000-5,000 per month for brands to more affordable levels, improving adherence.
Consult your endocrinologist to assess suitability, especially if you have cardiovascular risks or obesity. Common side effects include nausea and gastrointestinal issues, which often subside; tools like Shotlee can help track symptoms and dosing schedules for better management.
Company Performance in a Competitive Arena
Firms with strong chronic and sub-chronic exposure outperformed the market. Sun Pharma held market leadership with an 8.4 per cent share, alongside double-digit MAT March 2026 growth from Intas Pharma, Glenmark, and Torrent Pharma.
These leaders benefit from diversified portfolios, enabling them to navigate pricing headwinds through volume gains and new launches.
Challenges and Future Outlook for IPM and GLP-1
While IPM growth is robust, Ind-Ra highlights risks: regulatory pricing controls and GLP-1 competition could erode margins. Yet, the shift to chronic-led products offsets these, with volumes indicating structural demand.
Comparing to alternatives, GLP-1s outperform DPP-4 inhibitors or SGLT2s in weight loss but require injections for some formulations. Safety profiles are favorable long-term, with cardiovascular benefits outweighing GI risks for eligible patients.
Key Takeaways: What This Means for Stakeholders
- IPM expanded 10.1% YoY in March 2026, led by 15.5% anti-diabetic growth.
- GLP-1 market reached Rs 15.8B MAT, tripling YoY on generic semaglutide volumes.
- Chronic therapies drive sustainable momentum into FY27 at 9-10% growth.
- Companies like Sun Pharma (8.4% share) thrive amid competition.
- Patients gain from affordable access; discuss with doctors for personalized plans.
Conclusion: Navigating India's Evolving Pharma Dynamics
India's IPM is on a strong trajectory, with GLP-1 generics catalyzing anti-diabetic innovation. As volumes and chronics lead, stakeholders must monitor pricing and regulations. For patients, this signals broader access to effective metabolic therapies—actionable steps include routine check-ups and adherence tracking for optimal health outcomes.
